CLABD
Core One Labs Inc Common Shares
stock OTC

> VANCOUVER, British Columbia, Aug. 07, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that the scientific team of its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has initiated the next step in their clinical development designs for the use of their patent pending psychedelic formulations AKO001 and AKO003, in the treatment of ischemic stroke and depression, respectively. [These studies will further enhance the Company’s knowledge supporting the use of psychedelics as strong candidates in the treatment of these serious neurological and mental health conditions.](https://www.globenewswire.com/en/news-release/2021/08/07/2276738/0/en/Core-One-Labs-to-Move-Its-Psychedelic-Formulations-for-the-Treatment-of-Stroke-and-Depression-Toward-Clinical-Development.html)
 
And more
> [Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion](https://www.globenewswire.com/news-release/2021/08/05/2275192/0/en/Core-One-Labs-Virtual-Town-Hall-Reveals-Company-is-Nearing-Production-of-Biosynthesized-Psilocybin-Breakthrough-In-the-Psychedelic-Space-Expected-Upon-Successful-Completion.html)
 
> [Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment](https://www.globenewswire.com/en/news-release/2021/07/21/2266177/0/en/Core-One-Labs-Akome-Biotech-Protects-New-AKO003-Ketamine-Based-Breakthrough-Drug-Formulation-For-Depression-Treatment.html)